BSE filing, NSE: COCKERILL. Summary written from the filing by ALFA Finder's alert engine.
John Cockerill India Ltd: key numbers
- Share price
- ₹6,941.00
- Market cap
- ₹3,427 Cr
- Revenue (annual)
- ₹357.6 Cr
- Net profit (annual)
- ₹10.31 Cr
- P/E (TTM)
- 291.1×Sector 51.7×
- Promoter holding
- 70.44%+0.00% QoQ
- FII holding
- 0.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from John Cockerill India Ltd
All →John Cockerill India Other Announcement
John Cockerill India Limited filed its Regulation 74(5) certificate for the quarter ended September 30, 2026, confirming no dematerialization requests were received.
John Cockerill India Management Change
John Cockerill India Limited announced the resignation of Mr. Vivek Mukund Bhide from his position as Non-Executive Non-Independent Director, effective September 15, 2026.
John Cockerill India Bags ₹200 Cr Order
John Cockerill India Ltd secured a Rs. 200 Crore contract from A1 Iron & Steel Tanzania Ltd for supply and installation of industrial equipment. The project spans ten months.
- Value
- ₹200.0 Cr
- Execution
- 10 months from August 2026
John Cockerill India Earnings Call Transcript: Key Takeaways
Management projects confidence via a massive 4,500 Cr order book while navigating transitional costs from global entity consolidation. Revenue fell sequentially due to project lifecycles, but YoY growth remains robust.
John Cockerill India Management Change
John Cockerill India Limited appointed Deepak Prabhakar Chindarkar as Chief Financial Officer, effective August 24, 2026. He brings over 36 years of finance leadership experience.
John Cockerill India Investor Presentation: Key Takeaways
John Cockerill India (JCIL) reported strong YoY standalone revenue growth of 82% in Q2 CY26. Consolidation of Chinese, German, and Belgian entities marks a strategic shift towards an integrated global platform.
Other regulatory approval announcements
All →Gland Pharma Regulatory Approval
Gland Pharma received USFDA approval for Methylprednisolone Acetate Injectable Suspension USP in multiple vial formats. The product is bioequivalent to Pfizer's Depo-Medrol in a ~$214M US market.
City Union Bank Regulatory Approval
City Union Bank disclosed RBI approval for appointing Shri Sankaran G as Executive Director (Whole-time Director) for three years. The board appointment and formal disclosures will follow later.
- Execution
- Three years from the date of taking charge
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.
Som Distilleries & Breweries Regulatory Approval
Som Distilleries received manufacturing licences for its Bhopal plant from the Madhya Pradesh Excise Department, plus product label and rate approvals. Manufacturing and sales are expected to resume soon.
AGI Infra Regulatory Approval
Agi Infra received RERA registration PBRERA-SAS80-PR1452-102026 from Punjab RERA for its Utopia by AGI group housing project in New Chandigarh. The registration is valid until 30 March 2031.
- Execution
- Valid up to March 30, 2031
360 One Wam Regulatory Approval
360 ONE Distribution Services' IFSC branch, a subsidiary of 360 ONE WAM, received an IFSCA Certificate of Registration to act as broker dealer, clearing member, depository participant, research entity and distributor. This is a regulatory licence authorising new activities in the IFSC.